Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101

Anti-programmed cell death protein 1 (PD-1) therapy has shown promising efficacy in hepatocellular carcinoma (HCC), but its response rates in advanced HCC are lower than 20%. A critical reason for this is the imbalance between CD8(+) T cells and tumor burden. Here, a novel concept of vascular disrup...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Xin, Shen, Na, Lou, Yan, Yu, Haiyang, Wang, Yue, Liu, Linlin, Tang, Zhaohui, Chen, Xuesi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058708/
https://www.ncbi.nlm.nih.gov/pubmed/33897892
http://dx.doi.org/10.7150/thno.58164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058708/
https://www.ncbi.nlm.nih.gov/pubmed/33897892
http://dx.doi.org/10.7150/thno.58164

Ejemplares similares